

PAPER

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Dalton Trans.*, 2020, **49**,
16419Received 29th March 2020,
Accepted 15th July 2020

DOI: 10.1039/d0dt01182g

rsc.li/daltonResponsive fluorinated nanoemulsions for ^{19}F
magnetic resonance detection of cellular hypoxia†Rahul T. Kadakia,[‡] Da Xie,[‡] Hongyu Guo, Bailey Bouley, Meng Yu[‡] and
Emily L. Que[‡]*

We report two highly fluorinated Cu-based imaging agents, **CuL₁** and **CuL₂**, for detecting cellular hypoxia as nanoemulsion formulations. Both complexes retained their initial quenched ^{19}F MR signals due to paramagnetic Cu^{2+} ; however, both complexes displayed a large signal increase when the complex was reduced. DLS studies showed that the **CuL₁** nanoemulsion (**NE CuL₁**) had a hydrodiameter of approximately 100 nm and that it was stable for four weeks post-preparation. Hypoxic cells incubated with **NE CuL₁** showed that 40% of the Cu^{2+} taken up was reduced in low oxygen environments.

Introduction

Hypoxia in solid tumor cancers results from inadequate O_2 delivery to these rapidly dividing cells, resulting in O_2 deficiency. This leads to increased levels of hypoxia inducible factor (HIF-1), which regulates the cells' ability to adapt to the new environment.^{1,2} If left untreated, the cells can become resistant to chemotherapy and cause malignant proliferation.^{3–6} Therefore, early diagnosis of hypoxic cancer cells is vital for tumor excision to avoid metastasis and secondary malignant tumor growths. An additional effect of hypoxia is a more reducing intracellular environment, which can be used for selective targeting of therapeutic and diagnostic agents. Among the imaging agents that have been developed to target hypoxia,^{7–14} ^{64}Cu ATSM (ATSM = diacetyl-bis(N^4 -methylthiosemicarbazone)) has been used as a positron emission tomography (PET) agent that functions *via* reduction of the Cu^{2+} complex and retention in hypoxic cells, however this agent requires the use of radioactive materials.^{15,16}

Magnetic resonance imaging (MRI) is the most widely used imaging modality to diagnose cancer and can be used to image whole organisms with high depth penetration without employing ionizing radiation. However, early tumor detection is difficult as the spatial and contrast resolution between cancerous growths and surrounding normal tissue is poor. As an emerging alternative, ^{19}F MRI can be used as there is no detectable fluorine in the body and, thus, any signal present

will originate from exogenous agents. Moreover, the ^{19}F nucleus provides comparable characteristics: 100% isotopic abundance, nuclear spin of $\frac{1}{2}$, 83% MR signal receptivity compared to ^1H , and further, the carbon-fluorine bond is biostable.¹⁷

Previously, we have demonstrated the use of fluorinated CuATSM imaging agents as “turn-on” probes for cellular hypoxia.^{7–9} These agents use paramagnetic Cu^{2+} , which serves as a powerful paramagnetic relaxation enhancement (PRE) source that attenuates ^{19}F MR signal due to T_2 shortening.^{7–9,17–21} Following reduction to Cu^+ in hypoxic cells and subsequent demetallation, the ^{19}F signal is fully restored, furnishing a signal turn-on in this environment. For these agents to be a viable option for *in vivo* studies, the need for elevated fluorine concentration on individual probes increases, to allow an overall brighter MRI signal. Unfortunately, the hydrophobic CuATSM scaffold and fluorine atoms decrease aqueous solubility. Therefore, synthesizing a highly fluorinated CuATSM complex also requires a new delivery formulation: nanoemulsions.

Nanoemulsions are nano-sized liquid particles that consist of an oil droplet core, which assists in the dissolution of hydrophobic molecules, and a layer of emulsifier, which is necessary to reduce excess interfacial energy and prevent aggregation (Fig. 1).^{22,23} Common emulsifiers are amphiphilic molecules such as phospholipids and pegylated molecules.²⁴ Importantly, a number of ^{19}F MRI nanoemulsion formulations have been employed to deliver perfluorinated carbon-based agents for *in vivo* imaging.^{25–29} By encapsulating the prepared Cu^{2+} -based probes into nanoemulsions, we envisioned that the complexes would maintain high fluorine spin density while staying miscible within the aqueous environment. Herein, we present two CuATSM-derived complexes, **CuL₁** and **CuL₂** (Fig. 1), with 18 and 36 equivalent fluorines, respectively. The

Department of Chemistry, The University of Texas at Austin, 105 E 24th St Stop A5300, Austin, TX 78712, USA. E-mail: emilyque@cm.utexas.edu

†Electronic supplementary information (ESI) available. CCDC 1993045. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d0dt01182g

‡These authors contributed equally.




Fig. 1 (A) Chemical structures for CuL_1 and CuL_2 . (B) Oil-in-water-nanoemulsion composition.

CuL_1 complex forms stable nanoemulsions that display “turn-on” in ^{19}F MR modalities upon reduction, and preferential signal turn-on in hypoxic cells.

Results and discussion

Structural characterization

CuL_1 and CuL_2 incorporate multiple perfluoro-*tert*-butyl units to confer high fluorine density and a glucosamine moiety to tune the overall lipophilicity of the whole complex. Their syntheses are described in full in the ESI.† Single crystals of CuL_1 were grown by evaporation of a concentrated ethanol solution at room temperature and brown, needle-like crystals were collected. The X-ray structure (Fig. S1†) confirmed a square-planar Cu^{2+} center embedded in the $[\text{N}_2\text{S}_2]$ pocket, similar to the parent CuATSM complex.³⁰ Interestingly, hydrogen bonds were observed between two different glucosamine motifs within the crystal packing. The average distance between Cu^{2+} and ^{19}F nuclei was measured as 8.4 Å, a distance at which Cu^{2+} would attenuate the ^{19}F MR signal.¹⁷ Single crystals of CuL_2 did not form.

Solution state characterization

^{19}F NMR characterization. To characterize the effect of Cu^{2+} on the ^{19}F NMR signal in our complexes, we obtained spectra and measured relaxation times of H_2L_1 , CuL_1 , H_2L_2 , and CuL_2 . The ^{19}F NMR spectra (Fig. S2†) of CuL_1 and CuL_2 demonstrated that Cu^{2+} broadens the ^{19}F signal in these complexes as compared to their respective ligands H_2L_1 and H_2L_2 . The relaxation times (Table 1) of the fluorine atoms decreased by roughly 30-fold for T_1 and 100-fold for T_2 . The larger fold of decrease in T_2 is consistent with the longer electronic relaxation time T_{1e} of the square planar Cu^{2+} center.^{31,32} The

Table 1 ^{19}F NMR parameters for 3 mM H_2L_1 , CuL_1 , H_2L_2 , and CuL_2 in d_6 -DMSO at room temperature at 9.4 T

	H_2L_1	CuL_1	H_2L_2	CuL_2
δ (ppm)	−70.0	−69.9	−70.0	−70.0
T_1 (ms)	590	20.4	675	22.2
T_2 (ms)	360	N/A ^a	333	N/A ^a
T_2^* (ms)	157	4.3	78.2	2.2

^a Due to the fast transverse relaxation for CuL_1 and CuL_2 , the T_2 was too short to be measured.

singlet peak observed for all prepared ligands and complexes indicated that the fluorine atoms are all magnetically equivalent, which is a benefit for maximizing the signal-to-noise ratio (SNR) in ^{19}F MR-based sensing.

Cyclic voltammetry. To understand the redox properties of CuL_1 and CuL_2 , the $\text{Cu}^{2+}/\text{Cu}^+$ redox potentials were determined by cyclic voltammetry in DMF (Fig. S3†). Measured half potentials of −0.62 V for CuL_1 and −0.60 V for CuL_2 were close to the reported values for the parent CuATSM complex (−0.63 V vs. SCE), revealing the potential for these complexes to target hypoxic cells.³³ Due to the presence of the quaternary carbon, the electron-withdrawing perfluoro-*tert*-butoxide and glucosamine moiety did not significantly change the reduction potential of the Cu^{2+} centers. This observation also indicates other R groups (instead of glucosamine) could be incorporated into this molecular scaffold to further functionalize or solubilize the complex. The ΔE_p values of CuL_1 and CuL_2 indicate that the reduction of CuL_1 is quasi-reversible while the reduction of CuL_2 is irreversible. Considering the different coordination preferences between Cu^+ and Cu^{2+} , the large bulkiness of the functional groups on H_2L_2 could result in a lower stability for $[\text{Cu}^+\text{L}_2]$ than $[\text{Cu}^+\text{L}_1]$, thus making the reduction process for CuL_2 less reversible than CuL_1 .

Preparation of nanoemulsion

Formulation. To improve incorporation of these complexes into aqueous media, an oil-in-water nanoemulsion formulation strategy was employed. H_2L_1 , CuL_1 , H_2L_2 , and CuL_2 nanoemulsions (namely, NE H_2L_1 , NE CuL_1 , NE H_2L_2 , and NE CuL_2) were prepared following published literature.²⁶ Lecithin, Milli-Q water, and safflower oil were mixed and heated at 80 °C to form the emulsion mixture. H_2L_1 , CuL_1 , H_2L_2 , and CuL_2 were dissolved in DMSO and the hot, pre-made emulsion was added directly to the DMSO solution, vortexed to create a crude emulsion, and ultrasonicated at 0 °C to afford a stock nanoemulsion (Scheme S2†). Unfortunately, upon reduction of NE CuL_2 with $\text{Na}_2\text{S}_2\text{O}_4$, both NE CuL_2 and the reduced NE CuL_2 gave similar T_2^* values and chemical shifts, making them difficult to differentiate under MR settings. Therefore, all future studies were performed with NE CuL_1 .

Size determination. The size distribution of NE CuL_1 was evaluated by dynamic light scattering (DLS). In water and various buffered environments, NE CuL_1 displayed a hydrodynamic diameter of ~100 nm with PDI ≤ 0.20 (Table 2). These

Table 2 Size distribution of NE CuL₁ in water and different buffers determined by dynamic light scattering (DLS)



Solvent/buffer	Average size (nm)	PDI
Water	93.3 ± 0.7	0.20
PBS	94.5 ± 0.3	0.18
HEPES	97.9 ± 0.2	0.20
RPMI (w/o FBS)	98.0 ± 0.4	0.19
DMEM (w/o FBS)	105.7 ± 0.8	0.16

results are consistent with reported results on similar systems^{34,35} and suggest effective formation of the nanoemulsion formulation. Transmission electronic microscopy (TEM) was employed to visualize the morphology of the prepared NE CuL₁, using neutral ammonium phosphomolybdate staining to improve contrast.²³ Therefore, as shown in Fig. 2, the nanoemulsions appeared as bright sphere-like structures with a size distribution of 81 ± 19 nm, which correlated well with DLS results. Energy-Dispersive X-ray Spectroscopy (EDS) of a single nanoemulsion revealed an even inner distribution of copper and sulfur elements, further confirming the successful preparation of a nanoemulsion containing the CuL₁ complex.

Nanoemulsion stability. The stability of both ligand and complex nanoemulsions was assessed by DLS (size) and ¹⁹F NMR (fluorine content). The stability of the NE CuL₁ was also assessed by inductively coupled plasma-optical emission spectroscopy (ICP-OES) to evaluate the copper content within the nanoemulsion. As shown in Fig. S4,† at 100 μM [Cu²⁺], the prepared NE CuL₁ displayed great aqueous stability with marginal change (<5%) in both its average size and the polydispersity index (PDI). However, at 5 mM [Cu²⁺], the NE CuL₁ is prone to aggregation and showed an increase in its average hydrodyn-

amic diameter and a decrease in PDI. Interestingly, although the size distribution of 5 mM NE CuL₁ changed over the course of 28 days, the copper leaching was minimal (<5%), similar to the 100 μM NE CuL₁. Additionally, a 100 μM sample of the NE H₂L₁ was subjected to DLS and ¹⁹F NMR analysis over the course of four weeks after preparation. Compared to the NE CuL₁, the leaching of H₂L₁ within NE H₂L₁ was much faster when studied by ¹⁹F NMR, especially at a higher ligand concentration (Fig. S5†). While the 0.5 mM NE H₂L₁ showed 6% leaching after two weeks, the 5 mM NE H₂L₁ leaching increased to 20% during the same time. The increased cargo leaching for NE H₂L₁, as compared to NE CuL₁, is likely due to a more polar nature of H₂L₁ that encouraged its escape from the nanoemulsion.

Relaxation time determination. To understand the MR properties of CuL₁ and H₂L₁ within their nanoemulsion environments, ¹⁹F NMR spectra were taken for each nanoemulsion (Fig. 3A). NE H₂L₁ displayed an intense singlet peak at -70.5 ppm. On the other hand, NE CuL₁ gave a very broad peak at -70.7 ppm. Fluorine relaxation times (*T*₁ and *T*₂) were measured for both nanoemulsions (Table 3). NE H₂L₁ had a *T*₁ of 380 ms and a *T*₂ of 7.0 ms, which was much shorter compared to that of the DMSO solution of H₂L₁. The large decrease in *T*₂ is likely due to the viscous safflower oil core of the nanoemulsion and potential intermolecular aggregation due to hydrogen bonding between the glucose motifs as observed in the crystal packing. The *T*₁ relaxation time of NE CuL₁ was too

**Fig. 2** (A) Representative TEM image of NE CuL₁ negatively stained with neutral ammonium phosphomolybdate. Inset: Expanded view of a single nanoemulsion. (B) Size distribution of NE CuL₁ (*n* = 104). (C) Copper and sulfur elemental profiling of a single NE CuL₁ particle by Energy-Dispersive X-ray Spectroscopy (EDS).**Fig. 3** (A) ¹⁹F NMR spectra of 1.0 mM NE H₂L₁, NE CuL₁, and reduced NE CuL₁. (B) Phantom ¹⁹F MRI of 1.0 mM NE H₂L₁, NE CuL₁, and reduced NE CuL₁.**Table 3** ¹⁹F NMR parameters of 0.5 mM NE H₂L₁, NE CuL₁, and reduced NE CuL₁ at room temperature

	NE H ₂ L ₁	NE CuL ₁	NE CuL ₁ + Na ₂ S ₂ O ₄
δ (ppm)	-70.5	-70.7 ^a	-70.5
<i>T</i> ₁ (ms)	380	N/A ^b	440
<i>T</i> ₂ (ms)	7.0	N/A ^b	4.4
<i>T</i> ₂ [*] (ms)	7.0	0.4	4.4

^a The peak for NE CuL₁ was broad. ^b Due to the fast transverse relaxation for NE CuL₁, the *T*₁ and *T*₂ were too short to be measured.

short to measure and the T_2^* was 0.4 ms, consistent with its broad and nearly quenched signal.

Redox behavior. To determine if the chemical reduction of CuL_1 would successfully happen inside the nanoemulsion, 1.0 mM test-tube reactions between $\text{Na}_2\text{S}_2\text{O}_4$ and NE CuL_1 were carried out (Fig. 3A). Upon addition of $\text{Na}_2\text{S}_2\text{O}_4$, the characteristic orange-brownish color of CuL_1 disappeared immediately, and the whole nanoemulsion system turned off-white, consistent with reduction of Cu^{2+} to Cu^+ . The ^{19}F NMR characteristics of the reduced system were similar to the $\text{NE H}_2\text{L}_1$ ($\delta = -70.5$ ppm; $T_1 = 0.44$ s; $T_2 = 4.4$ ms) (Table 3). Therefore, while being encapsulated inside the nanoemulsion, CuL_1 was likely converted to H_2L_1 upon reduction. We note that there was no significant change to the ^{19}F NMR of $\text{NE H}_2\text{L}_1$ in the presence of $\text{Na}_2\text{S}_2\text{O}_4$ (Fig. S6†).

The reduction of the Cu^{2+} center within the nanoemulsion was further confirmed *via* UV-vis absorption and EPR spectroscopy (Fig. S7†). Before reduction, the UV-vis absorption spectrum of NE CuL_1 displayed a characteristic Cu^{2+} d-d absorption peak at 480 nm³⁶ and the EPR spectral pattern was well correlated to a square planar Cu^{2+} center^{37,38} with $g_{\text{iso}} = 2.061$ and $A_{\text{Cu}} = 106$ G. Post reduction, all these spectral features were lost, consistent with reduction of Cu^{2+} . Importantly, the UV-vis absorption spectrum of NE CuL_1 was recovered upon exposing the reduced NE CuL_1 to air, indicating that the binding of Cu^{2+} by H_2L_1 was not perturbed by the presence of the nanoemulsion formulation.

Phantom MR images. Phantom ^{19}F MR imaging for 1.0 mM $\text{NE H}_2\text{L}_1$, NE CuL_1 , and reduced NE CuL_1 were performed. Fast-low-angle-shot (FLASH) pulse sequence was applied to allow tracking of species with short T_2 values. As shown in

Fig. 3B, Cu^{2+} effectively quenches the ^{19}F MR signal and the signal-to-noise ratio for NE CuL_1 was on the same level as noise ($\text{SNR} = 2.2$). On the other hand, an intense signal was captured for the $\text{NE H}_2\text{L}_1$ ($\text{SNR} = 12$) and the reduced NE CuL_1 ($\text{SNR} = 7.6$), each with the same ^{19}F concentration as the NE CuL_1 . These results demonstrated a “turn-on” response in the ^{19}F MR imaging modality when CuL_1 is reduced and converted to H_2L_1 within nanoemulsion formulations and hold promise for potential ^{19}F MR imaging-based studies.

Cell studies

Cytotoxicity and cell uptake. To evaluate the nanoemulsion's ability to act as a biological probe, cell studies were performed with MCF-7 breast cancer cells. Cytotoxicity of the NE CuL_1 was tested using a Live/Dead assay under both normoxic and hypoxic conditions. Fluorescence imaging data showed >95% viability of the nanoemulsion incubated cells in both normoxic and hypoxic environments (Fig. S8†). To track the copper content of the MCF-7 cells, cell uptake studies were performed on normoxic and hypoxic cells after 2, 4, and 6-hour incubation (ICP-OES). As shown in Fig. S9,† a gradual increase in copper uptake was observed for increasing incubation times. At 6 hours, the cellular copper level was 3.2 ± 0.1 fmol per cell, which should give a cellular fluorine content of ~ 60 fmol per cell. When comparing the copper uptake between normoxic and hypoxic conditions, we saw no differences. This similarity could be due to the fact that CuL_1 was encapsulated in the nanoemulsion and uptake and retention of the nanoemulsion is not dependent on the oxygen level. Uptake studies at 4 °C, a temperature at which energy-dependent active transportation is blocked, showed 9-fold less cellular copper content after




Fig. 4 (A) Confocal images of MCF-7 cells incubated with NE CuL_1 (top row), the fluorescent dye (middle row), and both NE CuL_1 and the fluorescent dye (bottom row). (B) Quantitative comparison of intracellular fluorescence of ~ 100 cells at different incubation conditions. (C) Whole cell ^{19}F NMR of $\text{NE H}_2\text{L}_1$ (top) and NE CuL_1 (middle) in normoxic (20% O_2) environment and NE CuL_1 (bottom) in hypoxic (0.1% O_2) environment.

4 hours compared to studies at 37 °C, consistent with an energy-dependent cell uptake pathway. The energy-dependent cell uptake of the **NE CuL₁** correlated well with the vesicular character of these formulations.²⁴

To visualize the uptake of **NE CuL₁**, MCF-7 cells were incubated with a fluorescent ZnSalen complex that has been reported to stain the hydrophobic interior of lipid droplets (Fig. 4A).³⁹ MCF-7 cells were incubated with **NE CuL₁** only, with the fluorescent dye only, and with both fluorescent dye and **NE CuL₁**, respectively. As expected, no fluorescence was observed within the cells when only **NE CuL₁** was administered (Fig. 4A, top). With incubation of the fluorescent dye itself, cellular fluorescence was weak (Fig. 4A, middle). When the cells were treated with both **NE CuL₁** and the fluorescent dye (Fig. 4A, bottom), an intense intracellular fluorescence was observed, exhibiting an enhancement of fluorescence by nearly 3-fold compared to cells incubated with the fluorescent molecule only (Fig. 4B). A closer look at the image revealed dot-like red fluorescence inside the cytoplasm, corresponding to the vesicular character of the nanoemulsions. These results further confirmed efficient uptake of the nanoemulsions into cells.

Cellular hypoxia reduction studies. **NE CuL₁** was employed for hypoxia detection through ¹⁹F NMR spectroscopy (Fig. 4C). As a positive control, normoxic MCF-7 breast cancer cells were first cultured with 100 μM **NE H₂L₁** for 4 hours. The cells were collected, transferred into an NMR tube, and a ¹⁹F NMR spectrum was taken with 5-fluorocytosine (5FC) as external reference. A broad peak was recorded at −70.6 ppm. This result indicated that inside the cytosol, the **NE H₂L₁** stayed intact and its fluorine signal was detectable. Additional MCF-7 cells were incubated with **NE CuL₁** under both normal (20%) and low (0.1%) oxygen tension. Only under the low oxygen tension was a peak at −70.6 ppm observed, indicating the selective reduction of **NE CuL₁** in the cells grown under hypoxic conditions. At 20% O₂, no ligand signal was detected; the trace signal of perfluoro-*tert*-butanol might have come from the slight decomposition of the complex inside the cells. To quantify the cellular reduction of copper inside the cells, the reduced copper content was estimated by ¹⁹F NMR spectroscopy (where the peak integration represents the fluorine content of the reduced complex and therefore the amount of copper follows the molar ratio between Cu and F with **CuL₁**, which is 1 : 18), and the total copper content quantified *via* ICP-OES. It was therefore determined that roughly 40% of **CuL₁** was reduced in the cytosol under hypoxic conditions.

Conclusions

In summary, we demonstrated a CuATSM-based nanoemulsion sensor system that selectively displays ¹⁹F NMR signal in hypoxic cells. CuATSM derivative, **CuL₁**, was embedded within oil-in-water nanoemulsions which displayed ideal morphology and aqueous stability. Switching of the ¹⁹F MR signal *via* tuning of copper redox state was demonstrated by adding

chemical reducing agents and the effective reduction of copper was verified by spectroscopic methods. Selective detection of cellular hypoxia was further achieved in breast cancer cells grown under both normoxic (20% O₂) and severe hypoxic (0.1% O₂) conditions, where ~40% of the Cu²⁺ uptaken (~1.3 fmol per cell) was estimated to be reduced by cellular machinery. These results thus provide solid evidence that responsive oil-in-water nanoemulsion systems can be used to detect changes in cellular environments using ¹⁹F magnetic resonance. Ongoing work includes synthesizing a complex with a larger T₂^{*} and higher cellular uptake for *in vivo* applications.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was funded by start-up funds from UT-Austin (EQ), a grant from the Welch Foundation (F-1883) (EQ) and a grant from the National Science Foundation (CHE-1945401) (EQ). We thank Dr Vincent Lynch for X-ray crystallography support. We acknowledge the Biomedical Imaging Center at UT Austin for access to their facilities. Some NMR spectra were obtained on a Bruker AVIII HD 500 that was funded by an NIH grant (J. Sessler, 1 S10 OD021508-01).

References

- 1 A. E. Greijer and E. van der Wall, *J. Clin. Pathol.*, 2004, **57**, 1009–1014.
- 2 E. M. Hammond, M. C. Asselin, D. Forster, J. P. O'Connor, J. M. Senra and K. J. Williams, *Clin. Oncol.*, 2014, **26**, 277–288.
- 3 P. Vaupel, A. Mayer and M. Höckel, *Methods Enzymol.*, 2004, **381**, 335–354.
- 4 W. R. Wilson and M. P. Hay, *Nat. Rev. Cancer*, 2011, **11**, 393–410.
- 5 A. R. Padhani, K. A. Krohn, J. S. Lewis and M. Alber, *Eur. Radiol.*, 2007, **17**, 861–872.
- 6 R. J. Gillies and R. A. Gatenby, *Cancer Metastasis Rev.*, 2007, **26**, 311–317.
- 7 D. Xie, S. Kim, V. Kohli, A. Banerjee, M. Yu, J. S. Enriquez, J. J. Luci and E. L. Que, *Inorg. Chem.*, 2017, **56**, 6429–6437.
- 8 D. Xie, T. L. King, A. Banerjee, V. Kohli and E. L. Que, *J. Am. Chem. Soc.*, 2016, **138**, 2937–2940.
- 9 R. T. Kadakia, D. Xie, D. Martinez, M. Yu and E. L. Que, *Chem. Commun.*, 2019, **55**, 8860–8863.
- 10 J. Pacheco-Torres, P. López-Larrubia, P. Ballesteros and S. Cerdán, *NMR Biomed.*, 2011, **24**, 1–16.
- 11 Q. N. Do, J. S. Ratnakar, Z. Kovács and A. D. Sherry, *ChemMedChem*, 2014, **9**, 1116–1129.

- 12 S. Takahashi, W. Piao, Y. Matsumura, T. Komatsu, T. Ueno, T. Terai, T. Kamachi, M. Kohno, T. Nagano and K. Hanaoka, *J. Am. Chem. Soc.*, 2012, **134**, 19588–19591.
- 13 D. J. Yang, S. Wallace, A. Cherif, C. Li, M. B. Gretzer, E. E. Kim and D. A. Podoloff, *Radiology*, 1995, **194**, 795–800.
- 14 E. Lopci, I. Grassi, A. Chiti, C. Nanni, G. Cicoria, L. Toschi, C. Fonti, F. Lodi, S. Mattioli and S. Fanti, *Am. J. Nucl. Med. Mol. Imaging*, 2014, **4**, 365–384.
- 15 A. L. Văvere and J. S. Lewis, *Dalton Trans.*, 2007, 4893–4902.
- 16 J. J. Vaquero and P. Kinahan, *Annu. Rev. Biomed. Eng.*, 2015, **17**, 385–414.
- 17 D. Xie, M. Yu, R. T. Kadakia and E. L. Que, *Acc. Chem. Res.*, 2019, 2–10.
- 18 J. S. Enriquez, M. Yu, B. S. Bouley, D. Xie and E. L. Que, *Dalton Trans.*, 2018, **47**, 15024–15030.
- 19 H. Chen, X. Tang, X. Gong, D. Chen, A. Li, C. Sun, H. Lin and J. Gao, *Chem. Commun.*, 2020, **56**, 4106–4109.
- 20 S. Mizukami, R. Takikawa, F. Sugihara, Y. Hori, H. Tochio, M. Wälchli, M. Shirakawa and K. Kikuchi, *J. Am. Chem. Soc.*, 2008, **130**, 794–795.
- 21 K. H. Chalmers, E. De Luca, N. H. Hogg, A. M. Kenwright, I. Kuprov, D. Parker, M. Botta, J. I. Wilson and A. M. Blamire, *Chemistry*, 2010, **16**, 134–148.
- 22 Y. Singh, J. G. Meher, K. Raval, F. A. Khan, M. Chaurasia, N. K. Jain and M. K. Chourasia, *J. Controlled Release*, 2017, **252**, 28–49.
- 23 V. Klang, N. B. Matsko, C. Valenta and F. Hofer, *Micron*, 2012, **43**, 85–103.
- 24 M. Jaiswal, R. Dudhe and P. K. Sharma, *3 Biotech*, 2015, **5**, 123–127.
- 25 A. A. Kislukhin, H. Xu, S. R. Adams, K. H. Narsinh, R. Y. Tsien and E. T. Ahrens, *Nat. Mater.*, 2016, **15**, 662.
- 26 I. Tirotta, A. Mastropietro, C. Cordiglieri, L. Gazzera, F. Baggi, G. Baselli, M. G. Bruzzzone, I. Zucca, G. Cavallo, G. Terraneo, F. Baldelli Bombelli, P. Metrangolo and G. Resnati, *J. Am. Chem. Soc.*, 2014, **136**, 8524–8527.
- 27 J. M. Janjic and E. T. Ahrens, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2009, **1**, 492–501.
- 28 T. Nakamura, H. Matsushita, F. Sugihara, Y. Yoshioka, S. Mizukami and K. Kikuchi, *Angew. Chem., Int. Ed.*, 2015, **54**, 1007–1010.
- 29 K. Akazawa, F. Sugihara, M. Minoshima, S. Mizukami and K. Kikuchi, *Chem. Commun.*, 2018, **54**, 11785–1788.
- 30 A. R. Cowley, J. R. Dilworth, P. S. Donnelly, E. Labisbal and A. Sousa, *J. Am. Chem. Soc.*, 2002, **124**, 5270–5271.
- 31 I. Bertini, P. Turano and A. J. Vila, *Chem. Rev.*, 1993, **93**, 2833–2932.
- 32 I. Bertini, C. Luchinat, G. Parigi and E. Ravera, *NMR of Paramagnetic Molecules*, Elsevier, Boston, 2 edn, 2017.
- 33 J. L. Dearling, J. S. Lewis, G. E. Mullen, M. J. Welch and P. J. Blower, *J. Biol. Inorg. Chem.*, 2002, **7**, 249–259.
- 34 J. M. Janjic, M. Srinivas, D. K. Kadayakkara and E. T. Ahrens, *J. Am. Chem. Soc.*, 2008, **130**, 2832–2841.
- 35 S. K. Patel, J. Williams and J. M. Janjic, *Biosensors*, 2013, **3**, 341–359.
- 36 R. Mukherjee, *Comprehensive Coordination Chemistry II*, Pergamon, Oxford, 2003.
- 37 J. Peisach and W. E. Blumberg, *Arch. Biochem. Biophys.*, 1974, **165**, 691–708.
- 38 S. Ushio and A. W. Addison, *J. Chem. Soc., Dalton Trans.*, 1979, 600–608.
- 39 J. Tang, Y. Zhang, H. Y. Yin, G. Xu and J. L. Zhang, *Chem. – Asian J.*, 2017, **12**, 2533–2538.